Tang Capital Management CAPR Position
ExitedTang Capital Management exited their position in CAPRICOR THERAPEUTICS, INC. (CAPR) in Q2 2025, after holding the stock for 2 quarters.
The position was first reported in Q1 2025 and has been tracked across 2 quarterly 13F filings.
2 other tracked funds also hold CAPR.
Short interest stands at 14.2% of float with 4.8 days to cover, indicating significant bearish positioning against the stock.
About CAPRICOR THERAPEUTICS, INC.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Full company profile →Short Interest
14.2%
4.8 days to cover
Tang Capital Management CAPR Position History
Frequently Asked Questions
Does Tang Capital Management own CAPR?
No. Tang Capital Management exited their position in CAPRICOR THERAPEUTICS, INC. (CAPR) in Q2 2025. They previously held the stock for 2 quarters.
How many hedge funds own CAPR?
2 specialist biotech hedge funds currently hold CAPR, including RA Capital Management, RTW Investments. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Tang Capital Management first buy CAPR?
Tang Capital Management's position in CAPR was first reported in Q1 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Tang Capital Management's CAPR position increasing or decreasing?
Tang Capital Management completely exited their CAPR position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CAPRCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Tang Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →